Cardiovascular

Atrial fibrillation: stroke prevention with CHA2DS2-VASc and HAS-BLED

Clinical Overview and When to Suspect Atrial Fibrillation

— Palpitations, dyspnea, fatigue, exercise intolerance, lightheadedness

— Cryptogenic stroke or TIA in an older adult — pursue prolonged ambulatory monitoring (30-day patch or implantable loop recorder)

— New heart failure exacerbation, unexplained tachycardia, syncope

— Incidental irregularly irregular pulse on routine exam or smartwatch alert

— Paroxysmal, persistent, long-standing persistent, and permanent AF all carry similar stroke risk at equivalent CHA₂DS₂-VASc scores

— Anticoagulation decisions are driven by risk score, not AF burden or pattern (with rare exceptions like device-detected subclinical AF <24 hours)

Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting ~6 million US adults; prevalence rises sharply with age (>10% over age 80).

Stroke risk is the central concern: AF confers a ~5-fold increased risk of ischemic stroke, and AF-related strokes are larger, more disabling, and more often fatal than non-AF strokes.

Mechanism: stasis in the left atrial appendage (LAA) → thrombus formation → systemic embolization, most commonly to the cerebral circulation.

When to suspect AF:

Risk factors (HEART-CHASE): Hypertension, Ethanol, Age, Rheumatic/valvular disease, Thyrotoxicosis, CHF, HOCM, Apnea (OSA), Sleep deprivation, Endurance exercise; also obesity, diabetes, CKD, post-cardiac surgery.

Classification matters less for stroke prevention than people assume:

Board pearl: A patient with a single 5-minute episode of paroxysmal AF and CHA₂DS₂-VASc of 3 needs the same anticoagulation as a patient in permanent AF with the same score. Don't be tricked into withholding OAC because AF was "brief."

Step 3 framing emphasizes the ambulatory longitudinal decision: identify AF → risk stratify → start and maintain appropriate stroke prevention → monitor bleeding and adherence over years, not just at the index visit.

Presentation Patterns and Key History

— Palpitations (irregular, often described as "fluttering" or "skipping")

— Dyspnea on exertion, reduced exercise tolerance

— Fatigue, generalized weakness — sometimes the only complaint in elderly

— Lightheadedness or near-syncope (especially with rapid ventricular response or pauses on conversion)

— Chest discomfort, even without coronary disease, from rate-related demand ischemia

— Syncope (suggests RVR, pauses, or underlying structural disease)

— Acute focal neurologic deficit → stroke/TIA from cardioembolism

— Acute heart failure (pulmonary edema from loss of atrial kick + tachycardia)

— Hemodynamic instability → consider immediate synchronized cardioversion

— Prior stroke, TIA, or systemic embolism (each worth 2 points on CHA₂DS₂-VASc)

— Hypertension, diabetes, CHF, vascular disease (MI, PAD, aortic plaque)

— Age (65–74 = 1 point; ≥75 = 2 points)

— Sex (female = 1 point only if other risk factors present; alone, female sex does not require OAC)

— Prior major bleed, labile INRs, alcohol use ≥8 drinks/week, NSAID/antiplatelet use, falls (controversial — not a contraindication to OAC by itself)

— Renal/hepatic function, uncontrolled HTN (SBP >160)

Symptom spectrum is wide — from completely asymptomatic (often older patients, found on routine ECG) to severely symptomatic with hemodynamic compromise.

Classic symptom cluster:

Red-flag presentations demanding urgent evaluation:

Targeted history for stroke risk and anticoagulation decision:

Bleeding history for HAS-BLED:

Key distinction: Patient's symptoms drive rate vs. rhythm strategy and quality-of-life decisions; CHA₂DS₂-VASc drives stroke prevention. These are independent decisions — even an asymptomatic patient in well-rate-controlled AF with score ≥2 (men) or ≥3 (women) needs lifelong anticoagulation.

Step 3 management: Always ask about smartwatch/wearable-detected AF — if a patient reports a device alert, obtain a 12-lead ECG or ambulatory monitor to confirm before initiating therapy. Do not anticoagulate based on PPG tracings alone.

Physical Exam Findings and Hemodynamic Assessment

— Irregularly irregular pulse — pathognomonic finding on palpation

— Variable intensity of S1 (varying diastolic filling times)

— Pulse deficit — apical heart rate > radial pulse rate (some beats don't generate palpable pulse)

— Untreated AF often has ventricular rate 110–180 bpm

— Very rapid rates (>150) → consider WPW with AF (delta waves on ECG, can degenerate to VF — avoid AV nodal blockers!)

— Slow ventricular response without rate-control drugs → suspect underlying conduction disease (sick sinus, AV block) — these patients may need pacemaker before/with rate control

— Hypotension, altered mental status, ischemic chest pain, acute pulmonary edema → unstable AF → urgent synchronized DC cardioversion (typically 120–200 J biphasic)

— Stable but symptomatic → IV rate control (metoprolol, diltiazem) or elective rhythm control

— Thyrotoxicosis: tremor, lid lag, warm moist skin, goiter, weight loss

— Mitral stenosis: opening snap, diastolic rumble at apex — "valvular AF" (rheumatic MS or mechanical valve) → warfarin only, no DOACs

— Heart failure: elevated JVP, S3, crackles, edema

— Hyperadrenergic state: alcohol withdrawal, sepsis, PE, post-op

— Always perform focused neuro exam — silent strokes are common in AF

— Document baseline cognition; AF is independently associated with cognitive decline and vascular dementia

Classic exam triad:

Loss of "a" wave in jugular venous pulsations (no organized atrial contraction).

Rate assessment:

Hemodynamic assessment is the first triage step:

Look for clues to underlying etiology:

Neurologic exam:

Board pearl: In a hemodynamically unstable AF patient, do not delay cardioversion to obtain a TEE or start anticoagulation — shock first, anticoagulate after. The risk of stroke from emergent cardioversion is real but outweighed by ongoing instability.

CCS pearl: Order continuous cardiac monitoring, IV access ×2, full vitals q15 min, and place defibrillator pads on any AF patient with borderline hemodynamics before initiating rate or rhythm control.

Diagnostic Workup — Initial Labs, Imaging, and ECG

— Absence of discrete P waves, irregular fibrillatory baseline

— Irregularly irregular R-R intervals

— Narrow QRS unless aberrancy, bundle branch block, or pre-excitation

— Look for evidence of prior MI, LVH, pre-excitation (WPW), prolonged QT (affects antiarrhythmic choice)

— 24–48 hour Holter monitor for frequent symptoms

— 14–30 day event/patch monitor (e.g., Zio patch) for infrequent symptoms

— Implantable loop recorder for cryptogenic stroke workup — detects AF in ~30% over 3 years

— TSH — rule out hyperthyroidism (reversible cause)

— CBC — anemia, infection

— BMP — electrolytes (K, Mg), renal function (drives anticoagulant choice and dosing)

— LFTs — affects DOAC selection (avoid in Child-Pugh C)

— Troponin if chest pain or hemodynamic instability

— BNP/NT-proBNP if heart failure suspected

— Coagulation panel (PT/INR, aPTT) as baseline before anticoagulation

— HbA1c, lipid panel for cardiovascular risk modification

— Assesses LV function, atrial size, valvular disease (especially mitral stenosis)

— Identifies "valvular AF" (rheumatic MS, mechanical valve) → warfarin only

— Helps guide rhythm control candidacy (very large LA, severely depressed EF impact success)

12-lead ECG is diagnostic and mandatory:

If ECG is normal but suspicion is high (paroxysmal AF):

Initial laboratory workup (every new AF):

Chest X-ray: cardiomegaly, pulmonary edema, alternative diagnosis (PE, pneumonia precipitating AF).

Transthoracic echocardiogram (TTE) is required in all new AF:

Board pearl: "Valvular AF" for anticoagulation purposes means moderate-to-severe mitral stenosis or mechanical heart valve — these patients require warfarin (target INR 2–3 for MS; 2.5–3.5 for most mechanical valves). All other valvular abnormalities (MR, AS, bioprosthetic valves, repaired valves) are managed like non-valvular AF and DOACs are preferred.

Step 3 management: Document a baseline creatinine clearance using Cockcroft-Gault — this drives DOAC dose adjustment, not eGFR from the lab, especially in elderly low-weight patients.

Diagnostic Workup — Advanced or Confirmatory Studies

— Gold standard for visualizing LAA thrombus

— Indicated before early cardioversion (<48 hr rule has exceptions) if anticoagulation status uncertain

— TEE-guided cardioversion strategy: if no LAA thrombus seen → cardiovert, start anticoagulation, continue ≥4 weeks regardless of CHA₂DS₂-VASc

— Alternative: 3 weeks of therapeutic anticoagulation before cardioversion + 4 weeks after (the "3-and-4 rule")

— Pulmonary vein anatomy mapping before ablation

— LA size and fibrosis assessment (MRI with late gadolinium) — predicts ablation success

— Alternative to TEE for LAA thrombus exclusion in selected patients

— CRYSTAL-AF trial: implantable loop recorder dramatically increases AF detection vs. conventional monitoring

— Standard of care after cryptogenic stroke if AF suspected

Transesophageal echocardiography (TEE) — the key advanced test for stroke prevention decisions:

Cardiac CT/MRI:

Prolonged ambulatory monitoring in cryptogenic stroke:

Sleep study (polysomnography): strongly consider in obese, hypertensive, or recurrent AF patients — OSA treatment improves AF recurrence rates after cardioversion or ablation.

Exercise stress testing: indicated if rate-related symptoms with exertion, suspected CAD, or before initiating flecainide/propafenone (must exclude structural heart disease and ischemia).

Genetic testing: rarely indicated; consider in young patients with strong family history of AF or unexplained cardiomyopathy.

Key distinction: The <48 hour cardioversion window without prior anticoagulation is not absolute — recent guidelines emphasize that even short-duration AF can produce thrombus, particularly in patients with high CHA₂DS₂-VASc. When in doubt, perform TEE or anticoagulate first.

Board pearl: After any cardioversion (electrical or pharmacologic), patients require at least 4 weeks of anticoagulation because of "atrial stunning" — mechanical atrial function lags behind electrical recovery, perpetuating thrombus risk. After 4 weeks, long-term anticoagulation is decided by CHA₂DS₂-VASc, not by rhythm status.

Step 3 management: In cryptogenic stroke patient, the answer is usually extended cardiac monitoring (≥30 days), not a one-time ECG or 24-hr Holter.

Risk Stratification — CHA₂DS₂-VASc and HAS-BLED

— CHF/LV dysfunction — 1

— Hypertension — 1

— Age ≥75 — 2

— Diabetes — 1

— Stroke/TIA/thromboembolism — 2

— Vascular disease (prior MI, PAD, aortic plaque) — 1

— Age 65–74 — 1

— Sex category female — 1 (only counts if ≥1 other risk factor)

— Score 0 (men) / 1 (women, sex-only) → no anticoagulation

— Score 1 (men) / 2 (women) → reasonable to consider OAC; shared decision-making

— Score ≥2 (men) / ≥3 (women) → anticoagulation recommended

— Hypertension uncontrolled (SBP >160) — 1

— Abnormal renal (Cr >2.3 or dialysis) or liver function — 1 each

— Stroke history — 1

— Bleeding history or predisposition — 1

— Labile INR (TTR <60%) — 1

— Elderly (>65) — 1

— Drugs (antiplatelet, NSAID) or alcohol ≥8/week — 1 each

CHA₂DS₂-VASc score — estimates annual ischemic stroke risk in non-valvular AF:

Anticoagulation thresholds (2023 ACC/AHA/HRS guideline):

HAS-BLED score — estimates annual major bleeding risk on OAC:

Critical interpretation rule: HAS-BLED ≥3 = high bleeding risk, but this is NOT a contraindication to anticoagulation — it identifies patients needing closer monitoring and modifiable risk factor reduction (BP control, stop NSAIDs, limit alcohol, address falls).

Board pearl: Many HAS-BLED risk factors overlap with CHA₂DS₂-VASc (HTN, age, stroke) — patients at highest stroke risk often have highest bleeding risk, but net clinical benefit still favors anticoagulation in nearly all such patients.

Key distinction: "HAS-BLED informs, does not exclude." Use it to modify bleeding risk, not to withhold therapy. Fall risk alone is not a reason to avoid OAC — a patient would need ~295 falls per year on warfarin to offset stroke benefit.

Step 3 management: Document CHA₂DS₂-VASc and HAS-BLED in the chart at every AF visit and reassess annually — risk factors accumulate over time (especially age).

Pharmacotherapy — Anticoagulation First-Line Regimens

— Apixaban (Eliquis) — 5 mg BID; 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5. Often preferred in CKD, elderly, high bleeding risk.

— Rivaroxaban (Xarelto) — 20 mg daily with evening meal; 15 mg daily if CrCl 15–50

— Dabigatran (Pradaxa) — 150 mg BID; 75 mg BID if CrCl 15–30. Higher GI bleeding in elderly.

— Edoxaban (Savaysa) — 60 mg daily; 30 mg if CrCl 15–50 or weight ≤60 kg. Avoid if CrCl >95 (paradoxical reduced efficacy).

— Target INR 2.0–3.0 (2.5–3.5 for most mechanical mitral valves)

— Bridging with LMWH only for very high stroke risk (recent stroke, mechanical valve) — most AF patients do not need bridging for procedures

— Time in therapeutic range (TTR) >70% defines good control

— Idarucizumab — dabigatran reversal

— Andexanet alfa — apixaban, rivaroxaban reversal (limited availability, expensive)

— 4-factor PCC (Kcentra) — warfarin reversal (plus IV vitamin K); also used off-label for factor Xa inhibitor bleeding when andexanet unavailable

— FFP — only if PCC unavailable

— Mechanical heart valve (RE-ALIGN halted — dabigatran inferior to warfarin)

— Moderate-severe mitral stenosis

— Severe renal impairment (CrCl <15) — apixaban has limited data at very low GFR; warfarin preferred in dialysis, though apixaban 5 mg BID is increasingly used

— Antiphospholipid syndrome (especially triple-positive) — warfarin preferred

— Pregnancy — use LMWH

DOACs (direct oral anticoagulants) are first-line for non-valvular AF — preferred over warfarin per current guidelines (lower intracranial hemorrhage, no monitoring, fewer interactions):

Warfarin — required for valvular AF (mitral stenosis, mechanical valves) and a reasonable choice when DOACs contraindicated:

Reversal agents (must know):

DOAC contraindications:

Board pearl: Apixaban has the most favorable bleeding profile, especially lower GI bleeding vs. other DOACs — preferred in elderly and CKD.

Step 3 management: Always stop antiplatelets when starting OAC for AF unless there's a strong separate indication (recent PCI <12 months, recent ACS) — adding aspirin to OAC nearly doubles bleeding without reducing stroke.

Non-Pharmacologic Stroke Prevention and Rate/Rhythm Control

— WATCHMAN device — percutaneous LAA closure for patients with non-valvular AF + high stroke risk + contraindication to long-term OAC (e.g., recurrent GI bleeding, intracranial hemorrhage)

— Requires short-term anticoagulation post-procedure (typically 45 days warfarin + aspirin, then DAPT, then aspirin alone)

— Surgical LAA exclusion may be performed during concomitant cardiac surgery (LAAOS III trial showed stroke benefit)

— Reduces AF burden and improves quality of life; does NOT eliminate need for anticoagulation in patients with CHA₂DS₂-VASc ≥2

— First-line option in selected symptomatic paroxysmal AF, especially if young; class I in HFrEF with AF (CASTLE-AF: reduced mortality)

— Beta-blockers (metoprolol, carvedilol) — first-line, especially with HFrEF, CAD

— Non-dihydropyridine CCBs (diltiazem, verapamil) — avoid in HFrEF (negative inotrope)

— Digoxin — adjunct, especially in sedentary elderly or HFrEF; narrow therapeutic window

— Target resting HR <110 bpm (lenient) acceptable per RACE II if asymptomatic and EF preserved; stricter <80 if symptomatic

— Flecainide/propafenone — only if no structural heart disease or CAD (proarrhythmic risk)

— Amiodarone — most effective but high toxicity burden (thyroid, lung, liver, skin, eye); reserved for structural heart disease

— Dofetilide, sotalol — require inpatient initiation with QT monitoring

— Dronedarone — contraindicated in permanent AF and HFrEF (PALLAS, ANDROMEDA)

Left atrial appendage occlusion (LAAO):

Catheter ablation (pulmonary vein isolation):

Rate control (initial strategy for most asymptomatic or minimally symptomatic patients):

Rhythm control (consider if symptomatic, young, first episode, HF):

CCS pearl: For new AF with RVR, the ordered set is: continuous monitoring, IV access, telemetry, IV metoprolol 5 mg q5 min × 3 or IV diltiazem 0.25 mg/kg bolus then drip, recheck rate/BP, anticoagulation decision per CHA₂DS₂-VASc, TTE, TSH.

Board pearl: Rate vs. rhythm control showed equivalent mortality in AFFIRM, but recent EAST-AFNET 4 trial supports early rhythm control (within 1 year of diagnosis) for improved cardiovascular outcomes — exam may favor early rhythm control in newly diagnosed symptomatic patients.

Special Populations — Elderly and Renal/Hepatic Impairment

— Stroke risk increases sharply, but so does bleeding risk — anticoagulation still provides net benefit in nearly all

— Apixaban preferred — best safety profile in age >80, low weight, CKD

— Avoid undertreating: age alone is NOT a reason to withhold OAC

— Address modifiable bleeding risks: stop NSAIDs, manage HTN aggressively, deprescribe aspirin if no separate indication

— Falls assessment: as noted, falls alone are not a contraindication

— CrCl 30–50: apixaban full dose (unless 2 of 3 criteria); rivaroxaban 15 mg; dabigatran 150 mg BID (caution); edoxaban 30 mg

— CrCl 15–30: apixaban 2.5–5 mg BID; rivaroxaban 15 mg; dabigatran 75 mg BID (US only); avoid edoxaban

— CrCl <15 or dialysis: traditionally warfarin; apixaban 5 mg BID increasingly used (RENAL-AF, AXADIA suggest similar outcomes); avoid rivaroxaban, dabigatran, edoxaban

— Use Cockcroft-Gault (not MDRD/CKD-EPI) for DOAC dosing — this is what the trials used

— Child-Pugh A: DOACs generally safe

— Child-Pugh B: avoid rivaroxaban; use apixaban or warfarin with caution

— Child-Pugh C: avoid all DOACs; warfarin only with careful monitoring

— Cognitive impairment increases nonadherence and bleeding risk

— Once-daily DOACs (rivaroxaban, edoxaban) may improve adherence

— Consider LAAO if anticoagulation truly unsafe

Elderly (≥75 years):

Renal impairment — dose adjustments are critical:

Hepatic impairment:

Frailty and dementia:

Board pearl: The most common Step 3 trap: an 82-year-old woman with HTN, DM, prior stroke, CrCl 45, weight 58 kg — CHA₂DS₂-VASc = 7. Correct answer is apixaban 2.5 mg BID (meets 2 of 3 dose-reduction criteria: age ≥80, weight ≤60 kg). Don't confuse with full-dose apixaban or warfarin.

Step 3 management: Recheck renal function at least annually, more often (every 6 months) in elderly or CKD stage 3b+. A creatinine bump may require DOAC dose reduction or switch.

Special Populations — Pregnancy, Pre-Excitation, Athletes

— AF in pregnancy is rare but rising (older maternal age, congenital heart disease survival)

— Warfarin contraindicated in first trimester (teratogen — warfarin embryopathy) and near delivery (fetal hemorrhage); may be considered in 2nd trimester for mechanical valves

— DOACs contraindicated throughout pregnancy and breastfeeding (insufficient safety data, placental transfer)

— LMWH (enoxaparin) is preferred anticoagulant — does not cross placenta; dose-adjusted by anti-Xa levels

— Rate control: metoprolol or propranolol preferred; avoid atenolol (IUGR)

— Rhythm control: flecainide or sotalol if needed; cardioversion is safe in pregnancy

— Pre-excited AF can degenerate to VF — true emergency

— ECG shows irregular, wide-complex, very rapid tachycardia (often >250 bpm)

— AVOID AV nodal blockers (adenosine, beta-blockers, CCBs, digoxin, amiodarone IV) — they preferentially block AV node, accelerating conduction down accessory pathway

— Treatment: synchronized cardioversion if unstable; procainamide or ibutilide if stable

— Long-term: catheter ablation of accessory pathway

— Marathon runners, cyclists have 2–5× increased AF risk (atrial remodeling from chronic high stroke volume)

— Detraining or reducing endurance volume may reduce recurrence

— Anticoagulation decisions follow same CHA₂DS₂-VASc rules

— Treat the thyroid disease — AF often resolves with euthyroidism

— Anticoagulate while thyrotoxic (hypercoagulable state); reassess CHA₂DS₂-VASc after euthyroid

— Beta-blockers preferred for rate control

— Common (20–40% post-CABG); often transient

— Still carries long-term stroke risk — current guidelines recommend considering long-term anticoagulation if CHA₂DS₂-VASc warrants, even after AF resolves

Pregnancy:

Wolff-Parkinson-White (WPW) with AF:

Athletes and endurance exercise:

Hyperthyroidism-induced AF:

Post-operative AF (especially post-cardiac surgery):

Board pearl: WPW + AF + IV diltiazem = lethal mistake. The board buzzword is "irregular wide-complex tachycardia with delta waves" — go straight to procainamide or cardioversion.

Key distinction: Subclinical AF detected by pacemaker/ICD with episodes <24 hours in low-risk patients may not require anticoagulation (ARTESIA, NOAH-AFNET 6 nuanced); episodes >24 hours or high CHA₂DS₂-VASc → anticoagulate.

Complications and Adverse Outcomes

— Ischemic stroke — most feared; AF-related strokes have higher mortality and disability than other ischemic strokes

— Systemic embolism — mesenteric, renal, splenic, peripheral arterial occlusion

— Silent cerebral infarcts — contribute to cognitive decline and vascular dementia

— Intracranial hemorrhage — most feared bleeding event; DOACs reduce ICH by ~50% vs. warfarin

— GI bleeding — most common major bleeding; rivaroxaban, dabigatran, edoxaban higher than warfarin; apixaban similar to warfarin

— Genitourinary, retroperitoneal, soft tissue bleeding

— Management: hold OAC, supportive care, reversal agent (idarucizumab, andexanet, PCC) for major/life-threatening bleeds, transfusion as needed

— Chronic rapid ventricular response → reversible LV systolic dysfunction

— Diagnose with TTE showing reduced EF; treat with rate or rhythm control; EF often recovers within 3–6 months

— Loss of atrial kick reduces cardiac output by 20–30%, especially problematic in HFpEF and HCM

— Rapid rates worsen diastolic filling

— AF is independent risk factor for cognitive impairment, even without overt stroke

— Anticoagulation may slow decline

— Thromboembolic stroke (1–2% without proper anticoagulation; <0.5% with proper protocols)

— Bradyarrhythmias post-conversion (unmasking sick sinus syndrome)

— Skin burns from pads

— Fatigue, exercise intolerance, anxiety from palpitations

— Recurrent hospitalizations

Thromboembolic complications:

Bleeding complications of anticoagulation:

Tachycardia-mediated cardiomyopathy:

Heart failure exacerbation:

Cognitive decline and dementia:

Cardioversion-related complications:

Quality of life impact:

CCS pearl: For acute major bleeding on a DOAC, the CCS order set: hold DOAC, type and screen, CBC, coags, renal function, IV access, fluid resuscitation, transfusion if Hgb <7 (or <8 with cardiac disease), reversal agent (idarucizumab for dabigatran; andexanet alfa or 4F-PCC 50 U/kg for Xa inhibitors), GI/Neuro consult as appropriate, hold for 24–48 hours, then reassess restart timing.

Board pearl: Most patients with GI bleeding on OAC for AF should resume anticoagulation within 7–14 days after hemostasis — withholding long-term increases stroke and mortality more than recurrent bleeding.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Hemodynamic instability (hypotension, shock, AMS) — synchronized cardioversion

— Acute pulmonary edema from AF with RVR

— Active myocardial ischemia precipitated by AF

— Pre-excited AF (WPW) with very rapid rates

— Acute ischemic stroke — emergent neuro evaluation for thrombolysis/thrombectomy

— Major bleeding on anticoagulation (intracranial, hemodynamically significant GI)

— New AF with RVR not controlled with oral agents in ED

— Initiation of antiarrhythmics requiring monitoring (dofetilide, sotalol — mandatory 3-day inpatient initiation with QT monitoring; ibutilide post-administration monitoring)

— Planned cardioversion in patient not on therapeutic anticoagulation requiring TEE

— Acute heart failure exacerbation

— Significant comorbid acute illness (sepsis, PE, MI) precipitating AF

— Decision regarding rhythm control strategy or ablation

— Initiation of class I or III antiarrhythmics

— Recurrent AF despite rate control

— Evaluation for LAA occlusion device

— WPW with AF — needs electrophysiology referral for ablation

— Any acute stroke/TIA

— Cryptogenic stroke needing prolonged monitoring decisions

— Antiphospholipid syndrome

— Recurrent thrombosis despite anticoagulation

— Difficult anticoagulation decisions in cancer, hereditary thrombophilia

— Hemodynamically stable AF with controlled rate

— Initiation of beta-blockers, CCBs, DOACs

— Established patients with stable rhythm/rate strategy

Immediate ICU/ED indications:

Inpatient admission criteria:

Cardiology consultation indications:

Neurology consultation:

Hematology consultation:

Outpatient management is appropriate for:

Step 3 management: Newly diagnosed stable AF in clinic can be managed outpatient with: rate control (oral metoprolol or diltiazem), DOAC if CHA₂DS₂-VASc warrants, TTE within 1–2 weeks, follow-up in 2–4 weeks. Most new AF does NOT require admission.

CCS pearl: When transitioning a CCS AF case from ED to floor, reassess every 2 hours initially: vitals, telemetry rhythm, symptoms, urine output, lab trends (renal function, electrolytes especially K and Mg — replete to K >4, Mg >2).

Key Differentials — Other Atrial Arrhythmias

— Organized atrial rhythm at ~300 bpm with sawtooth flutter waves (especially in inferior leads II, III, aVF)

— Typical 2:1 conduction → ventricular rate ~150 bpm (suspect flutter when HR exactly ~150)

— Same stroke risk as AF — apply CHA₂DS₂-VASc, anticoagulate identically

— Cavotricuspid isthmus ablation is highly curative (>95% success) for typical flutter

— Irregular rhythm with ≥3 distinct P-wave morphologies, variable PR intervals

— Almost always associated with severe COPD exacerbation, hypoxia, theophylline toxicity

— Treat underlying disease; rate control with verapamil or metoprolol (caution with bronchospasm)

— Not an anticoagulation indication (unlike AF/flutter)

— Regular rhythm, P waves with abnormal morphology

— May respond to AV nodal blockers, beta-blockers, ablation

— Can mimic AF but underlying rhythm is sinus

— Treat trigger (caffeine, stress, infection)

— Regular, narrow QRS, no preceding P or inverted P after QRS

— Often slower; sometimes seen with digoxin toxicity

— Regular narrow-complex tachycardia, typically 150–250 bpm

— Responds to vagal maneuvers, adenosine

— Not AF — does not require anticoagulation

Atrial flutter:

Multifocal atrial tachycardia (MAT):

Atrial tachycardia (focal):

Sinus tachycardia with frequent PACs:

Junctional rhythm with retrograde P waves:

Supraventricular tachycardia (AVNRT, AVRT):

Key distinction: Irregularly irregular rhythm with no P waves = AF. Regular sawtooth pattern at HR ~150 = atrial flutter. ≥3 P-wave morphologies + COPD = MAT. Memorize these triggers — they are favorite stems.

Board pearl: Atrial flutter and AF coexist in ~50% of patients and behave identically for stroke risk purposes. Don't withhold anticoagulation just because the rhythm is "only flutter."

Step 3 management: A patient with COPD exacerbation and "irregular tachycardia" — before anticoagulating, look at the ECG. If MAT (multiple P-wave morphologies), treat the COPD, not the rhythm with OAC.

Key Differentials — Non-Arrhythmia Causes and AF Mimics

— Normal, especially in young patients; rate varies with respiration

— P waves present and uniform; not pathologic

— Can produce irregular pulse but ECG shows clear underlying rhythm with ectopic beats

— Irregular if mode-switching; check device interrogation

— Hyperthyroidism (may also cause AF)

— Pheochromocytoma — episodic HTN, headache, sweating

— Panic disorder, anxiety

— Caffeine, stimulants, sympathomimetics, cocaine

— Hypoglycemia

— Anemia (compensatory tachycardia)

— Pulmonary embolism — sinus tach but may precipitate AF

— PIRATES mnemonic: Pulmonary embolism/disease, Ischemia, Rheumatic heart disease, Anemia/atrial myxoma, Thyrotoxicosis, Ethanol/Endocarditis, Sepsis/Sleep apnea/Stimulants

— Holiday heart syndrome — binge alcohol → AF; resolves with abstinence

— Post-operative AF — especially post-cardiac surgery (20–40%)

— Sepsis-induced AF — common in ICU

— Treat the trigger

— Still anticoagulate during AF if CHA₂DS₂-VASc warrants

— Reassess after trigger resolved — many patients have recurrent AF months later, so consider monitoring

— Cryptogenic stroke — pursue extended monitoring

— Carotid stenosis, aortic atheroma, PFO with paradoxical embolism, hypercoagulable states, vasculitis

Sinus arrhythmia (respiratory):

Frequent PVCs/PACs:

Pacemaker-mediated rhythms:

Differential causes of palpitations (without AF):

Causes/triggers of new-onset AF to identify and treat ("reversible AF"):

Approach: when AF is found in setting of acute reversible trigger:

Stroke without AF:

Board pearl: Even transient AF triggered by a reversible illness (sepsis, post-op, thyrotoxicosis) increases lifetime stroke risk. Current guidelines suggest long-term anticoagulation should be considered in these patients based on CHA₂DS₂-VASc, with ambulatory monitoring to detect recurrence.

Key distinction: "Holiday heart" classically presents the Monday morning after a weekend of heavy drinking — typically a young patient, AF resolves spontaneously, but alcohol cessation counseling and longitudinal monitoring are essential.

Secondary Prevention, Discharge Medications, Long-Term Plan

— DOAC (apixaban most often selected) or warfarin per indication

— Document indication, dose, renal/hepatic-based adjustments, fall risk discussion, bleeding risk discussion

— Provide patient information sheet, medication card, reversal agent education for family

— Beta-blocker (metoprolol succinate, carvedilol) or non-DHP CCB (diltiazem ER, verapamil ER)

— Goal: resting HR <110 lenient; <80 if symptomatic

— Blood pressure <130/80 (HTN is the most modifiable AF risk factor)

— Weight loss — 10% loss reduces AF burden (LEGACY trial)

— OSA screening and CPAP — improves AF recurrence rates dramatically

— Alcohol reduction — <7 drinks/week; abstinence reduces AF recurrence (Voskoboinik et al., NEJM)

— Tobacco cessation

— Diabetes control (HbA1c <7%)

— Exercise — moderate; avoid extreme endurance training

— Caffeine — moderate; not necessary to eliminate

— Statin if ASCVD risk warrants

— Treat CAD, HF per guidelines

— Annual influenza, COVID-19, pneumococcal — reduces AF triggers from infection

— Aspirin should be stopped when OAC started for AF unless separate indication (recent ACS/PCI)

— Combination therapy ("triple therapy") only short-term post-PCI

Anticoagulation:

Rate or rhythm control medication continued or transitioned:

Risk factor modification — the "AF lifestyle bundle":

Cardiovascular risk modification:

Vaccinations:

Discontinue unnecessary antiplatelets:

Step 3 management: At discharge from new-onset AF, the order set: DOAC with first dose given before discharge, beta-blocker for rate, BP medication if needed, statin if indicated, CPAP referral if OSA suspected, cardiology follow-up in 2–4 weeks, TTE if not done, labs for renal/hepatic function in 4 weeks, patient education materials.

Board pearl: Aggressive risk factor modification (the "AF triple therapy" of weight loss, BP control, OSA treatment) is as effective as antiarrhythmic drugs for reducing recurrence — this is increasingly tested as a Step 3 ambulatory management question.

Follow-Up, Monitoring Parameters, and Counseling

— Initial follow-up: 2–4 weeks after new diagnosis or medication initiation

— Stable patients on chronic OAC: every 3–6 months initially, then at least annually

— Warfarin patients: INR every 1–4 weeks depending on stability; goal TTR >70%

— Renal function (Cr, CrCl) — at baseline, every 6–12 months, sooner if acute illness; more frequent if CKD stage 3+ (every 3–6 months)

— LFTs — annually

— CBC — at least annually to detect occult bleeding/anemia

— Hgb — investigate any drop with GI evaluation

— Resting ECG at follow-up

— Ambulatory monitor if uncontrolled symptoms or unclear rate control adequacy

— Watch for bradycardia (excessive rate control) — pulse <50 or symptoms

— Periodic ECG for QT (sotalol, dofetilide), QRS widening (flecainide)

— Amiodarone: TSH and LFTs every 6 months, CXR and PFTs annually, ophthalmologic exam annually, monitor for skin (blue discoloration), neuropathy, tremor

— Recognize symptoms of stroke (FAST — Face, Arm, Speech, Time)

— Recognize bleeding warning signs (melena, hematuria, easy bruising, headache)

— Medication adherence — even one missed DOAC dose creates significant risk window (short half-lives)

— Drug interactions — avoid NSAIDs, certain antibiotics (clarithromycin, fluconazole interact with DOACs)

— Procedure planning — most procedures only require 24–48 hour DOAC hold; coordinate with all providers

— Carry medication list and reversal agent info

Follow-up cadence:

Monitoring on DOAC therapy:

Reassess CHA₂DS₂-VASc and HAS-BLED annually — patients age into higher risk; new comorbidities accumulate

Rate control monitoring:

Rhythm control monitoring:

Patient counseling:

Board pearl: DOACs have short half-lives (~12 hours) — adherence is critical. A patient who misses 2 doses returns to baseline stroke risk within 24 hours. This contrasts with warfarin's longer effective duration.

Step 3 management: Before any elective procedure on a DOAC patient: assess bleeding risk of procedure, renal function, and stop DOAC 24 hours before low-bleeding-risk procedure, 48 hours before high-risk. Resume 24 hours after low-risk hemostasis, 48–72 hours after high-risk. No bridging needed for AF DOAC patients.

Ethical, Legal, and Patient Safety Considerations

— Genuine shared decision-making is required given the lifetime trade-off between stroke and bleeding

— Discuss numeric risks: e.g., "Your annual stroke risk is ~6% without treatment, reduced to ~2% with DOAC; major bleeding risk ~2–3% per year"

— Document discussion of alternatives (LAAO, no therapy) and patient preferences

— Use decision aids when available — improves comprehension and reduces decisional conflict

— Patients with dementia or cognitive impairment may lack capacity to weigh complex risk/benefit

— Involve surrogate decision-maker per state law and advance directives

— A diagnosis of dementia does NOT automatically remove decisional capacity for a specific decision

— DOAC dosing errors are common and dangerous — both underdosing (stroke) and overdosing (bleeding)

— Most common error: applying DOAC dose-reduction criteria incorrectly (e.g., reducing apixaban dose for age alone without other criteria)

— System-level fixes: EHR decision support, pharmacist verification, dedicated anticoagulation clinics

— Hospital discharge is a high-risk window for AF patients

— Errors include: failure to initiate OAC after new AF, failure to reconcile DOAC with home meds, premature discontinuation, missing follow-up appointment

— Step 3 management: Use a structured discharge checklist: confirm indication, correct dose for renal function, fill rx confirmed, follow-up scheduled, patient education delivered, primary care notified

— Patients/families often request OAC be withheld due to falls — counsel that benefit nearly always exceeds risk

— Document discussion and shared decision

— Syncope with AF and driving: state laws vary; physicians may have duty to report or counsel patients on driving restrictions, particularly for commercial drivers

— Black and Hispanic patients are less likely to be prescribed DOACs and more likely to be undertreated for AF — actively address access barriers

Informed consent for anticoagulation:

Capacity assessment:

Patient safety — medication errors:

Transition of care risks:

Fall risk and shared decision-making:

Mandatory reporting:

Health equity:

Board pearl: A common Step 3 ethics stem: elderly patient with AF and falls; family insists "don't anticoagulate, she'll fall and bleed." Correct answer: document shared decision-making conversation, present data showing net benefit of OAC, address modifiable fall risk (PT, home safety, medication review), and recommend continuing anticoagulation unless patient (with capacity) declines.

High-Yield Associations and Rapid-Fire Clinical Facts

— Dabigatran → idarucizumab

— Apixaban/rivaroxaban → andexanet alfa or 4F-PCC

— Warfarin → 4F-PCC + vitamin K

— AF <48 hrs and low risk → can cardiovert without prior anticoagulation, but anticoagulate ≥4 weeks after

— AF ≥48 hrs or unknown → 3 weeks anticoagulation OR TEE-guided, then cardiovert, then 4 weeks anticoagulation

— Long-term anticoagulation post-cardioversion: per CHA₂DS₂-VASc, not rhythm status

CHA₂DS₂-VASc points: CHF 1, HTN 1, Age ≥75 = 2, DM 1, Stroke/TIA = 2, Vascular 1, Age 65–74 = 1, Sex (F) 1

Anticoagulate when: CHA₂DS₂-VASc ≥2 (men) or ≥3 (women)

HAS-BLED ≥3: high bleeding risk → modify, don't withhold

Valvular AF = moderate-severe mitral stenosis or mechanical valve → warfarin only

DOAC of choice in CKD, elderly, low weight, high GI bleed risk: apixaban

DOAC to AVOID if CrCl >95: edoxaban

Reversal agents:

Cardioversion rules:

WPW + AF: avoid AV nodal blockers; use procainamide or cardioversion

Holiday heart: AF after binge alcohol; abstain

MAT: ≥3 P-wave morphologies, COPD — not AF, no OAC indication

AFFIRM: rate ≈ rhythm for mortality

EAST-AFNET 4: early rhythm control beneficial within 1 year of diagnosis

CASTLE-AF: ablation reduces mortality in HFrEF + AF

LEGACY: 10% weight loss reduces AF burden

RACE II: lenient (<110) rate control non-inferior to strict if asymptomatic and preserved EF

Atrial flutter = same stroke risk as AF; CTI ablation curative

Post-cardioversion: 4 weeks of anticoagulation mandatory due to atrial stunning

Tachycardia-induced cardiomyopathy: reversible with rate/rhythm control

Subclinical AF: device-detected episodes >24 hrs → anticoagulate; <24 hrs in low-risk → individualize

Aspirin has NO role in AF stroke prevention as monotherapy

Bridging is NOT needed for most AF patients on DOAC undergoing procedures

Board pearl: "Female sex" in CHA₂DS₂-VASc adds 1 point only if other risk factors are present — a 50-year-old woman with no other risk factors has CHA₂DS₂-VASc of 0, not 1.

Board Question Stem Patterns

— 72-year-old man, HTN, DM, prior TIA. Calculate: Age 65–74 (1) + HTN (1) + DM (1) + TIA (2) = 5. Anticoagulate.

— Pick: apixaban 5 mg BID (no dose reduction criteria met)

— 84-year-old woman, weight 55 kg, Cr 1.6. Apixaban dose? 2.5 mg BID (3 of 3 criteria: age ≥80, weight ≤60, Cr ≥1.5; ≥2 required for reduction).

— Patient with rheumatic mitral stenosis and AF. Best anticoagulant? Warfarin (DOACs contraindicated in moderate-severe MS).

— Young patient, irregular wide-complex tachycardia at 240 bpm, delta waves. Best treatment if stable? Procainamide or cardioversion. Avoid adenosine, beta-blocker, CCB, digoxin.

— Patient with AF for 2 weeks, hemodynamically stable. Best approach? Either 3 weeks anticoagulation then cardiovert, or TEE-guided cardioversion today + 4 weeks anticoagulation after.

— Patient on dabigatran with major GI bleed. Reversal? Idarucizumab. On apixaban with intracranial bleed? Andexanet alfa (or 4F-PCC if unavailable).

— COPD exacerbation, irregular rhythm. ECG: ≥3 P-wave morphologies. Diagnosis: MAT, not AF — treat COPD, NOT anticoagulate.

— Patient develops AF day 2 post-CABG. Resolves with metoprolol. CHA₂DS₂-VASc = 4. Long-term anticoagulation? Yes — still indicated; reassess at follow-up.

— 88-year-old with frequent falls and AF. Family wants OAC stopped. Best response? Shared decision-making, address fall risk, continue OAC unless patient with capacity declines.

— 65-year-old with ischemic stroke, normal carotids, normal initial monitoring. Next step? Implantable loop recorder or 30-day patch to detect occult AF.

— Patient CHA₂DS₂-VASc 4, HAS-BLED 3. Best action? Initiate OAC, manage modifiable bleeding risks. HAS-BLED does NOT contraindicate.

The classic CHA₂DS₂-VASc calculation stem:

The dose-reduction trap:

The valvular AF stem:

The WPW stem:

The cardioversion timing stem:

The bleeding-on-DOAC stem:

The MAT distractor:

The post-op AF stem:

The fall-risk ethics stem:

The cryptogenic stroke stem:

The HAS-BLED interpretation stem:

Board pearl: When the stem gives you both CHA₂DS₂-VASc and HAS-BLED scores, the question is almost always testing whether you'll be falsely deterred by bleeding risk — the answer is usually to anticoagulate and modify risks, not withhold.

One-Line Recap

In atrial fibrillation, stroke prevention is driven by CHA₂DS₂-VASc — anticoagulate (preferably with a DOAC) when score ≥2 in men or ≥3 in women, use HAS-BLED to identify and modify bleeding risk rather than withhold therapy, and reserve warfarin for valvular AF (moderate-severe mitral stenosis or mechanical valve).

High-yield bullet recaps:

The decision algorithm: Confirm AF on ECG → calculate CHA₂DS₂-VASc → if ≥2 (M) or ≥3 (W), anticoagulate → choose DOAC (apixaban preferred in elderly/CKD) unless valvular AF (warfarin) → calculate HAS-BLED to identify modifiable bleeders → monitor renal function, adherence, and reassess annually.

The dose-reduction rule for apixaban: 2.5 mg BID if ≥2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5. Memorize this — the most commonly tested dosing fact in AF on Step 3.

The cardioversion rule: <48 hrs and low risk → can cardiovert immediately; otherwise 3 weeks anticoagulation before OR TEE-guided + 4 weeks after regardless. Long-term OAC determined by CHA₂DS₂-VASc, not rhythm.

The WPW + AF rule: Irregular wide-complex tachycardia with delta waves → procainamide or synchronized cardioversion. AV nodal blockers (adenosine, beta-blocker, CCB, digoxin, IV amiodarone) can precipitate VF and are contraindicated.

The "do not withhold" rule: HAS-BLED ≥3, advanced age, fall risk, and prior bleeding are risk modifiers, not contraindications. Net clinical benefit favors anticoagulation in nearly all patients with score-appropriate AF.

The ambulatory management pearl: Risk factor modification — BP control, weight loss, OSA treatment, alcohol reduction — reduces AF burden as effectively as antiarrhythmics and improves cardiovascular outcomes long-term.

Step 3 management: Make the anticoagulation decision at every AF encounter, document it, and never let a transient or "resolved" episode of AF lull you into withholding indicated therapy — stroke risk persists.